Cell and Gene Therapy 2018
26 September / Zurich / Switzerland
Jean-François Mayol attending
A novel approach to therapeutic vaccines
AMAL aims to tackle the obstacles for effective anti-cancer therapy by stimulating a patient’s immune system in a unique way.
First-in-class immunisation technology
KISIMA®, our unique proprietary protein-based immunisation platform is self-adjuvanting and delivers several antigens in one single vaccine.
Transforming the prospects of cancer patients
We focus on the development of viable effective cancer therapies. Our most advanced asset is ATP128, a therapeutic vaccine for the treatment of metastatic colorectal cancers.
Strategic partnerships and collaborations
Our strategy is to develop KISIMA® and its current indications in oncology through to phase II, in-house or through strategic partnerships.
Latest
News
- Amal Therapeutics featured in September edition of BioPharma Dealmaker (Springer-Nature) 18 September 2018
- AMAL Therapeutics raises EUR 8 million (CHF 8.8 million) in first closing of Series B financing round 5 September 2017
- TOP 100 STARTUP AWARD 2016: on 14th September, Amal Therapeutics reached the top 10 14 September 2016
Events
4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
30 September – 3 October 2018 / New York, NY / USA
Jean-François Mayol attendingESMO – Munich 2018
19-23 October / Munich / Germany
Madiha Derouazi attending
Amal Therapeutics SA
c/o Fondation pour Recherches Médicales
64 av. de la Roseraie
1205 Geneva
Switzerland
